BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26563612)

  • 1. Serum amyloid A inhibits RANKL-induced osteoclast formation.
    Oh E; Lee HY; Kim HJ; Park YJ; Seo JK; Park JS; Bae YS
    Exp Mol Med; 2015 Nov; 47(11):e194. PubMed ID: 26563612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum amyloid A inhibits dendritic cell differentiation by suppressing GM-CSF receptor expression and signaling.
    Kim JC; Jung YS; Lee HY; Park JS; Bae YS
    Exp Mol Med; 2017 Aug; 49(8):e369. PubMed ID: 28857084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
    Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
    Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Amyloid A3 Secreted by Preosteoclasts Inhibits Parathyroid Hormone-stimulated cAMP Signaling in Murine Osteoblasts.
    Choudhary S; Goetjen A; Estus T; Jacome-Galarza CE; Aguila HL; Lorenzo J; Pilbeam C
    J Biol Chem; 2016 Feb; 291(8):3882-94. PubMed ID: 26703472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway.
    Niemi K; Teirilä L; Lappalainen J; Rajamäki K; Baumann MH; Öörni K; Wolff H; Kovanen PT; Matikainen S; Eklund KK
    J Immunol; 2011 Jun; 186(11):6119-28. PubMed ID: 21508263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rab11A Functions as a Negative Regulator of Osteoclastogenesis through Dictating Lysosome-Induced Proteolysis of c-fms and RANK Surface Receptors.
    Okusha Y; Tran MT; Itagaki M; Sogawa C; Eguchi T; Okui T; Kadowaki T; Sakai E; Tsukuba T; Okamoto K
    Cells; 2020 Oct; 9(11):. PubMed ID: 33142674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
    Tsujisawa T; Inoue H; Nishihara T
    J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms.
    Granholm S; Lundberg P; Lerner UH
    J Endocrinol; 2007 Dec; 195(3):415-27. PubMed ID: 18000304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.
    Grcević D; Lukić IK; Kovacić N; Ivcević S; Katavić V; Marusić A
    Clin Exp Immunol; 2006 Oct; 146(1):146-58. PubMed ID: 16968409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF Induction of NF-κB RelB Enhances RANKL-Induced Osteoclastogenesis by Promoting Inflammatory Macrophage Differentiation but also Limits It through Suppression of NFATc1 Expression.
    Zhao Z; Hou X; Yin X; Li Y; Duan R; Boyce BF; Yao Z
    PLoS One; 2015; 10(8):e0135728. PubMed ID: 26287732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAM19A5, a brain-specific chemokine, inhibits RANKL-induced osteoclast formation through formyl peptide receptor 2.
    Park MY; Kim HS; Lee M; Park B; Lee HY; Cho EB; Seong JY; Bae YS
    Sci Rep; 2017 Nov; 7(1):15575. PubMed ID: 29138422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
    Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum amyloid A inhibits osteoclast differentiation to maintain macrophage function.
    Kim J; Yang J; Park OJ; Kang SS; Yun CH; Han SH
    J Leukoc Biol; 2016 Apr; 99(4):595-603. PubMed ID: 26538527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.
    Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS
    Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligonucleotides: novel regulators of osteoclast differentiation.
    Zou W; Schwartz H; Endres S; Hartmann G; Bar-Shavit Z
    FASEB J; 2002 Mar; 16(3):274-82. PubMed ID: 11874977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.